An evaluation of the utility of routine laboratory monitoring of juvenile idiopathic arthritis (JIA) patients using non-steroidal anti-inflammatory drugs (NSAIDs): a retrospective review by Vora, Sheetal S et al.
Vora et al. Pediatric Rheumatology 2010, 8:11
http://www.ped-rheum.com/content/8/1/11
Open Access RESEARCH
BioMed  Central
© 2010 Vora et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research An evaluation of the utility of routine laboratory 
monitoring of juvenile idiopathic arthritis (JIA) 
patients using non-steroidal anti-inflammatory 
drugs (NSAIDs): a retrospective review
Sheetal S Vora*, Christine E Bengtson, Grant D Syverson and James J Nocton
Abstract
Background: No consensus evidence-based guidelines for the routine laboratory monitoring of children with JIA 
receiving non-steroidal anti-inflammatory drugs (NSAIDs) exist. The purpose of this study is to evaluate the clinical 
utility of routine laboratory monitoring of hemoglobin, transaminases, blood urea nitrogen, serum creatinine, and 
urinalysis in patients with juvenile idiopathic arthritis (JIA) receiving NSAIDs.
Methods: The medical records of 91 children with JIA followed between 1996 and 2006 were retrospectively reviewed 
for laboratory results and clinically significant adverse effects attributed to NSAID use. Laboratory abnormalities were 
documented, with potential adverse clinical sequelae, including if NSAID use was discontinued.
Results: Abnormal laboratory results were recorded for 24 of 91 patients. Nearly all abnormalities were mild and not 
associated with adverse clinical sequelae. All patients but one continued to receive NSAID therapy after the 
abnormality was detected.
Conclusions: Although detection of abnormal laboratory values occurred while on NSAIDs, these abnormalities did 
not correlate with adverse clinical signs and symptoms. The routine monitoring of laboratory tests in asymptomatic 
children treated with NSAIDs is of questionable utility.
Background
Juvenile idiopathic arthritis (JIA) continues to be the
most common chronic rheumatic disease affecting chil-
dren worldwide[1]. Optimal clinical management of JIA
is multidisciplinary and includes medication, physical
and occupational therapy, psychosocial support services,
and frequent monitoring of both disease activity and
potential adverse effects of treatment[2,3]. Non-steroidal
anti-inflammatory drugs (NSAIDs) are a mainstay of
treatment for almost all children with JIA at some stage of
their disease[4]. NSAIDs inhibit cyclo-oxygenase (COX),
decreasing the production of pro-inflammatory prosta-
glandins. Potential adverse effects of NSAIDs include
dermatitis, gastritis, hepatitis, and nephritis. These
adverse effects appear to be less common in children [4-
6], although the true incidence is unknown.
While the incidence of clinically associated adverse
effects due to NSAIDs appears to be relatively low in chil-
dren with JIA [4-6], many pediatric rheumatologists con-
tinue to perform routine laboratory monitoring in
children receiving chronic NSAID therapy. The Ameri-
can College of Rheumatology has developed NSAID lab-
oratory monitoring guidelines for adults with rheumatoid
arthritis [7], but these guidelines may not be appropriate
for children.
W e  r e v i e w e d  t h e  c h a r t s  o f  J I A  p a t i e n t s  r e c e i v i n g
NSAIDs followed at the Children's Hospital of Wisconsin
to determine the frequency of abnormal serum transami-
nases, blood urea nitrogen (BUN), serum creatinine (Cr),
hematuria, proteinuria, and hemoglobin (Hgb), and the
clinical outcome of those with an abnormality, including
any potential dermatitis, gastritis, hepatitis, and nephri-
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tis. Our aim was to estimate the frequency of significant
adverse clinical events associated with or attributed to
NSAID toxicity that would be detected by routine labora-
tory monitoring in children. This data may be useful in
guiding clinicians on the utility of routine laboratory test-
ing for children with JIA receiving NSAIDs.
Methods
We retrospectively reviewed the charts and laboratory
data of all children diagnosed with JIA and were followed
in the pediatric rheumatology clinic at the Children's
Hospital of Wisconsin between January 1996 and Sep-
tember 2006. All children met diagnostic criteria for
JIA[8,9]. Inclusion criteria included treatment with
NSAIDs for at least one month and a reported result on
at least one occasion of a minimum of one of the follow-
ing laboratory tests: aspartate aminotransferase (AST),
alanine aminotransferase (ALT), BUN, serum Cr, urinaly-
sis, or Hgb. Exclusion criteria included children with sys-
temic-onset JIA. In children treated with methotrexate
(MTX), laboratory results and clinical information were
recorded only during the time interval prior to the initia-
tion of MTX.
Laboratory data were reviewed and all abnormal labo-
ratory values were identified during the time period of
the study. The medical records of those with abnormal
laboratory values were reviewed further and any associ-
ated adverse clinical event was recorded. For the purpose
of this analysis, the discontinuation of NSAIDs was con-
sidered an adverse clinical event. Abnormal values of lab-
oratory tests were defined by the laboratory standards of
Children's Hospital of Wisconsin. In addition, patient age,
gender, subtype of JIA, the frequency of laboratory moni-
toring, the median time period while receiving NSAIDs,
the type of NSAID prescribed, and any additional medi-
cations prescribed were recorded for all patients.
Results
91 patients met the inclusion criteria and were included
in the data analysis. Of these, 62 (68%) had oligoarticular
disease and 29 (32%) had polyarticular disease (Table 1).
Seventy-four (81%) were female and 17 (19%) male. The
frequency of laboratory monitoring for individual
patients varied significantly. Serum AST was tested a
median of 2 times (range of 0-17) per patient, ALT 2
times per patient (range 0-14), and Hgb 2 times per
patient (range 0-15), serum Cr 1 time per patient (range
0-10) and urinalysis 0 times per patient (range 0-9).
Median duration of treatment with NSAIDs was 12
months (range 1.33-212.80). Naproxen was the most
c o m m o n l y  u s e d  N S A I D  ( 9 5 %  o f  p a t i e n t s ) .  N e a r l y  a l l
patients only received non-selective COX inhibiting
NSAIDs. All children received a single NSAID at a time.
Few children were receiving additional medications in
combination with NSAIDs, including biologic agents.
Total patient years of observation on NSAIDs for both
groups were 227.6 years. Specifically, 180.6 years for the
oligoarticular JIA subtype and 46.9 years for the polyar-
ticular JIA subtype.
Abnormal laboratory results were documented in 24/
91 (26%) patients. Of those with oligoarticular disease, 5
had abnormally low hemoglobin (9.9-11.6), 7 had ele-
vated serum transaminases (47-406), 9 had elevated BUN
(21-24), and 1 had trace proteinuria. Five patients had
abnormalities in two categories. In only one patient with
abnormalities in both serum transaminases and hemo-
globin was the NSAID discontinued (Table 2). In this
patient, the cause for the elevated transaminases
remained unclear even following liver biopsy. Of the 7
patients with polyarticular disease and detected labora-
tory abnormalities, 5 had abnormally low hemoglobin
(8.4-10.6), 1 had elevated BUN (22), and one had trace
proteinuria. None had more than one abnormality and
none had an abnormality requiring discontinuation of
NSAID therapy (Table 3). None of the 23 patients who
continued to receive NSAIDs had a clinically significant
adverse event that was felt to be secondary to the NSAID.
Discussion
The results of this study suggest that the routine labora-
tory monitoring of children with JIA receiving NSAIDs
alone has limited clinical utility. Although the frequency
of results falling outside the normal range as determined
by the laboratory was high (26%), most of these results
were mildly abnormal and clinically insignificant. There
was only one patient of the 91 included in our study in
which laboratory monitoring detected an abnormality
that led to discontinuation of the NSAID, and no patients
had an adverse event clearly related to NSAIDs and
detected by laboratory monitoring.
Our results are consistent with those of previous stud-
ies that have evaluated unselected cohorts of patients
with Juvenile Rheumatoid Arthritis (JRA). In a prospec-
tive study evaluating potential renal complications of
children with JRA receiving NSAIDs for 6 months or lon-
ger, 22 of 226 children (10%) had findings of microscopic
hematuria and/or proteinuria on one or more urinaly-
ses[5]. However, none of the children developed hyper-
tension, and in 21 of the patients the abnormalities
resolved spontaneously. In 1 patient, proteinuria contin-
ued 1 1/2 years later despite discontinuing NSAIDs,
therefore the relationship to NSAID use remained
unclear. A retrospective study of potential gastrointesti-
nal adverse effects of NSAIDs in an unselected cohort of
children with JRA concluded that the prevalence of clini-
cally significant gastropathy associated with NSAID use
in children with JRA was approximately 1%[4]. Of 702
children followed over 15 years, 10 events of clinical sig-Vora et al. Pediatric Rheumatology 2010, 8:11
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nificance described as esophagitis, gastritis, or peptic
ulcer disease were identified. The 10 events all occurred
in symptomatic children and no adverse events were dis-
covered by routine laboratory monitoring of asymptom-
atic patients [4].
Previous studies which have reported a wider range of
adverse events potentially related to NSAID use, includ-
ing some that are significantly higher, are limited by small
sample sizes and potential selection bias. In a United
Kingdom study of 13 children on NSAIDs with Juvenile
Chronic Arthritis (JCA) complaining of abdominal pain
or nausea, endoscopic findings were mild. Only one
patient had a single duodenal erosion at first endoscopy
to account for an unexplained drop in Hgb associated
with mild nausea. They determined that significant ulcer-
ation commonly seen in adults was not observed and
there was no correlation between the small number of
petechial lesions and mild gastritis with reported symp-
toms [10]. Mulberg et al. reported endoscopically-docu-
mented gastric injury in 13 of 17 patients (76%) with JRA
referred for epigastric abdominal pain, hematemesis,
guiac positive stools and/or iron deficiency anemia [11].
These patients were evaluated prospectively, however
only symptomatic patients were eligible. The evaluation
included a complete blood cell count and evaluation of
the stool for occult blood in all patients, followed by
endoscopy. There was a strong correlation between gas-
tric lesions and the presence of epigastric pain, regardless
of the presence of anemia or occult blood in stool. Simi-
larly, a retrospective study by Dowd et al. of children with
arthritis receiving NSAIDs reported that 16 of 47 patients
(34%) with symptoms of significant abdominal pain were
found to have gastric or duodenal radiographic injury
[12]. As with Mulberg's study, however, only patients with
gastrointestinal symptoms were evaluated. Our study did
not attempt to identify whether or not laboratory testing
was performed as a result of patients having symptoms
that might have been related to NSAID use. We instead
chose to review all laboratory testing performed during
this period, and identify all detected abnormalities.
Although we have concluded that routine laboratory
screening may have limited utility, laboratory testing of
select symptomatic children may be of greater clinical
value.
Table 1: Clinical characteristics of 91 children with JIA.
Patients
Characteristic No. %
Median age at onset (yr) 4 (0.1-15.7)
Gender
Female 74 81
Male 17 19
JIA onset subtype
Oligoarticular 62 68
Polyarticular 29 32
NSAID*
Naproxen 87 95
Meloxicam 4 4
Tolmetin 11 12
Ibuprofen 16 18
Rofecoxib 6 7
Diclofenac 8 9
Celecoxib 3 3
Nabumetone 2 2
Other Medications† 6 7
Median duration of treatment (yr)
Oligoarticular 1.5 (0.14-17.7)
Polyarticular 0.58 (0.11-9.8)
* Some patients may have been treated with more than one NSAID
(NSAIDs were never used simultaneously)
† Azathioprine (1), Etanercept (1), Hydroxychloroquine (4)Vora et al. Pediatric Rheumatology 2010, 8:11
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There are no consensus evidence-based guidelines for
the routine laboratory monitoring of children with JIA
receiving NSAIDs. Recommendations vary, but typically
include monitoring serum liver and renal function along
with a complete blood count (CBC) every 3 to 6 months
[9,13]. The Committee on Clinical Guidelines for moni-
toring drug therapy in adults with rheumatoid arthritis
recommends yearly CBC and liver function tests depend-
ing on type of NSAID [7]. The incidence of reported
NSAID adverse events in adult patients ranges from rare
(<1%) to uncommon (1-10%) to common (>10%) and
states that insufficient data is available to develop com-
plete evidence-based recommendations on the extent and
frequency of monitoring. Furthermore, the guidelines
also say it is unlikely that studies which gather such data
will be performed as toxicities in adults range form 0.1%
Table 2: Abnormalities of Laboratory Values in Oligoarticular JIA Patients.
Gender Variable Value Observations NSAID Continued
Female BUN 22 1 Yes
Female AST 47-48 2 Yes
Female ALT 45 1 Yes
Female BUN 22 1 Yes
Female AST 46 1 Yes
ALT 50-67 5 Yes
Female AST 57-267 4 Yes
ALT 67-406 4 Yes
BUN 23 1 Yes
Female BUN 21 1 Yes
Proteinuria Trace 1 Yes
Female Hgb 9.9-10.1 5 Yes
Female AST 49 1 No
ALT 50-107 5
Hgb 11 1
Female BUN 21 1 Yes
Male BUN 21 1 Yes
Female AST 48-49 2 Yes
Female BUN 21 1 Yes
Female BUN 25 1 Yes
Hgb 11 2 Yes
Female Hgb 10.8 1 Yes
Male ALT 44 1 Yes
BUN 24 2 Yes
Female * Hgb 11.6 1 Yes
* This patient was being treated with Tolmetin; all others were treated with Naproxen.
Table 3: Abnormalities in Polyarticular JIA Patients.
Gender Variable Value Observations NSAID Continued
Female Proteinuria Trace 1 Yes
Female Hgb 8.4 1 Yes
Female Hgb 10.1 1 Yes
Female Hgb 10.4 1 Yes
Female Hgb 10.2-10.6 3 Yes
Female Hgb 9.5-10.5 5 Yes
Female BUN 22 1 YesVora et al. Pediatric Rheumatology 2010, 8:11
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to 5% [7]. From this, it is expected that evidence is lacking
to support the application of these guidelines to the care
of children.
Our study has several limitations. As a result of the retro-
spective design, complete data was not available for all
patients. Patients were not followed for a consistent period
of time. The frequency of laboratory testing in general was
relatively low and was inconsistent among practitioners
and patients. There was no prior determination of either a
consistent frequency of laboratory testing or the evaluation
and management of children with abnormalities on test-
ing. Specifically, there were no consistent criteria for dis-
continuing NSAID therapy. Since the discontinuation of
NSAID was used as a surrogate for clinical significance,
and since this study was undertaken in a single pediatric
rheumatology clinic where the patients were cared for by a
small number of practitioners, this determination may be
susceptible to measurement bias. Sample size was also lim-
ited due to the lack of standardization regarding the fre-
quency of testing as well as the exclusion of many children
receiving methotrexate, who undergo routine laboratory
monitoring specifically due to the potential for methotrex-
ate to cause liver toxicity.
Conclusions
This study was conducted to understand the frequency of
abnormal laboratory tests associated with NSAID toxicity
and then determine if those abnormalities led to clinically
significant adverse events resulting in the discontinuation
of NSAIDs. Our study suggests that clinically significant
adverse events requiring the cessation of NSAIDs and
detected by routine laboratory monitoring appear to be
very infrequent. Therefore, frequent laboratory monitor-
ing in patients with JIA receiving NSAIDs is unlikely to be
cost effective. A prospective study to determine the inci-
dence and prevalence of significant adverse effects
detected by routine serial laboratory monitoring would
be helpful in further defining the utility of routine labora-
tory testing in this population.
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